Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 known ✓ | Q92731 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.83 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL9763204 | 1.00 | TSHR (0.83) | TSHRTP53LMNAMAPK1KDM4E | |
| Cadaverine Tartrate SCHEMBL31427568 | 0.91 | TSHR (1.00) | TSHRTP53LMNAKDM4ECYP2C9 | |
| Cadaverine Tartrate SCHEMBL1431070 | 0.91 | TSHR (1.00) | TSHRTP53LMNAKDM4ECYP2C9 | |
| Tartaric Acid SCHEMBL29430365 | 0.91 | TSHR (1.00) | TSHRTP53LMNAKDM4ECYP2C9 | |
| Cadaverine Tartrate SCHEMBL22768 | 0.91 | TSHR (1.00) | TSHRTP53LMNAKDM4ECYP2C9 | |
| Tartaric Acid SCHEMBL5762 | 0.91 | TSHR (1.00) | TSHRTP53LMNAKDM4ECYP2C9 | |
| Cadaverine Tartrate SCHEMBL1062721 | 0.91 | TSHR (1.00) | TSHRTP53LMNAKDM4ECYP2C9 | |
| Cadaverine Tartrate SCHEMBL116846 | 0.91 | TSHR (1.00) | TSHRTP53LMNAKDM4ECYP2C9 | |
| Cadaverine Tartrate SCHEMBL848 | 0.91 | TSHR (1.00) | TSHRTP53LMNAKDM4ECYP2C9 | |
| Cadaverine Tartrate SCHEMBL29382062 | 0.91 | TSHR (1.00) | TSHRTP53LMNAKDM4ECYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10577403-B2 | Modified polynucleotides for the production of secreted proteins | MODERNATX, INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-20190315824-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF SECRETED PROTEINS | MODERNATX, INC. (US) | 2019-10-17 | — | — | US | disclosed |
| US-8466296-B2 | Compounds and processes for preparing substituted aminomethyl-2,3,8,9-tetrahydro-7H-1,4-dioxino[2,3-e]indol-8-ones | LIGAND PHARMACEUTICALS (US) | 2013-06-18 | — | — | US | disclosed |
| US-20110021455-A1 | STERILISED SUCRALFATE GEL | PIERRE FABRE DERMO-COSMETIQUE (FR) | 2011-01-27 | — | — | US | disclosed |
| US-20100217012-A1 | COMPOUNDS AND PROCESSES FOR PREPARING SUBSTITUTED AMINOMETHYL-2,3,8,9-TETRAHYDRO-7H-1,4-DIOXINO[2,3-e]INDOL-8-ONES | NEUROGEN CORPORATION (US) | 2010-08-26 | — | — | US | disclosed |
| US-5962737-A | REACTING BENZALDEHYDE WITH NITROALKANE IN PRESENCE OF A TERTARY AMINE; THEN REDUCING USING LITHIUM ALUMINUM HYDRIDE | WEST DANIEL DAVID (US) | 1999-10-05 | — | — | US | disclosed |
| US-5830509-A | Microparticle complexes with 2-amino-1-phenylpropanol materials | NATURALLY SCIENTIFIC, INC. | 1998-11-03 | — | — | US | disclosed |
| EP-0107825-A1 | 1,3,4,6,7,11b-Hexahydro-7-aryl-2H-pyrazino (2,1-alpha) isoquinolines useful as intermediates and pharmaceutical compounds and methods of preparation | PENNWALT CORPORATION (US) | 1984-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315824-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF SECRETED PROTEINS | MSH2, POLRMT, SARNP | ESR2 4252/4885TSHR 1159/4885TP53 370/4885 |
| US-10577403-B2 | Modified polynucleotides for the production of secreted proteins | MSH2, POLRMT, SARNP | ESR2 4252/4885TSHR 1159/4885TP53 370/4885 |
| US-20100217012-A1 | COMPOUNDS AND PROCESSES FOR PREPARING SUBSTITUTED AMINOMETHYL-2,3,8,9-TETRAHYDRO-7H-1,4-DIOXINO[2,3-e]INDOL-8-ONES | MTNR1A, HTR3C, MTNR1B | ESR2 363/4885TSHR 42/4885TP53 4158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.